This isn't the Durability You Thought You Knew: A Fresh Perspective on Psoriasis - Video
Overview
In this short video, Matteo Megna, Associate Professor at the University of Naples Federico II, Naples, Italy, discusses durability as a novel clinical endpoint in moderate-to-severe psoriasis and its relevance in routine clinical practice.
He highlights that for patients with psoriasis consider two treatment goals as most important: achieving PASI 100 (complete skin clearance) as early as possible and maintaining this complete clearance over the long term. Evidence suggests that an earlier treatment response is associated with a higher likelihood of sustaining clinical outcomes in the long term. 1,2
The concept of PASI 100 durability combines both rapid achievement of complete skin clearance and its long-term maintenance. Two-year data from the ongoing large real-world PSoHO study demonstrated that ixekizumab achieved the highest proportion of patients with durable PASI 100 responses. 1,2
In addition, results from the IXORA study showed that ixekizumab was superior to the IL-23 inhibitor guselkumab in terms of the number of days patients spent without disease. 1,2 These findings suggest that ixekizumab may be an effective early intervention strategy, offering more disease-free days, better long-term quality-of-life control, and helping to reduce the cumulative life-course impairment experienced by patients with psoriasis. 1,2
Reference: 1. Pinter A, et al. Dermatol Ther (Heidelb). 2025. Online ahead of print. 2. Blome C, et al. Arch Dermatol Res. 2016;308(2):69-78. 3. Gorelick J, et al. Dermatol Ther (Heidelb). 2019;9(4):785-797. 4. Pinter A, et al. Dermatol Ther (Heidelb). 2025 (+suppl). Online ahead of print. 5. Blauvelt A, et al. Br J Dermatol. 2021;184(6):1047-1058.
PP-IX-IN-1011 | 16/12/2025
Eli Lilly and Company (India) Private Limited
For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001, India Ph.: +91-124-4753000/01 | www.lilly.com/in
For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com | For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.
This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals only for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.
© 2025 Eli Lilly and Company
